Anavex Life Sciences Corp (AVXL)

[falconer66a]

No Buy Out — Just a Service Contract

This is why I'd prefer to see a partnership where Anavex retains certain rights and ownership. From what I've heard, A371 has the potential to be the real game-changer. I see Blarcamesine as more of a stepping stone that paves the way for something bigger within the company's S1R platform.

Exactly, on every point.

First, a partnership, a corporate collaboration of some sort, where a collaborating company actually makes the Anavex drug(s) under contract, and perhaps another sales force collaboration where someone else distributes the drug, will be most favorable to Anavex and its shareholders.

But, yes, Anavex 3-71 will simply prove to be an even better drug than blarcamesine. It beats blarcamesine on every metric in both preclinical murine (lab rodent) trials and early human trials. Far smaller doses are required. Blarcamesine will be the first Anavex drug to gain FDA approval, most likely for Rett syndrome. Alzheimer’s and Parkinson’s disease dementia will follow.

By then Anavex will have millions of corporate earnings dollars, which will support big human clinical trials of Anavex 3-71; for a number of CNS and other conditions. It will beat blarcamesine in every respect.

Christopher Missling and all of the Anavex insiders know all of this far more precisely than we on the outside can imagine. I’m a biologist. I know exactly what data Anavex would have collected on all of their molecules. That always starts with tests in microorganisms, checking for induced genetic, DNA analomies. Then, in murines (lab rodents) checks for various systemic pathologies; disruptions of endocrine functions, embryonic development, carcinogenicities, etc. Lastly, the drugs’ effects on human diseases genetically inserted in the genomes of the lab rodents.

Be assured, Missling and company know far more than they’ve ever disclosed about their unique drugs. FAR bigger than just three CNS diseases. Watch. See what begins to appear with Anavex 3-71 in a year or two. It will be astonishing — and retained in the ownership of Anavex Life Sciences Corp. It will not be allowed to be bought out by any corporate suitor. Anavex will never be for sale. If Missling wanted a buy-out, he’d be proclaiming all sorts of “things we’ve discovered about our drugs.” Just the opposite. He says nothing. His stories will come to light at the right time.